References
- Food and Drug Administration. FDA. FDA; 2015 [cited 2023 Apr 2]. FDA Acts to Ensure Thyroid Drugs Don’t Lose Potency Before Expiration Date. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-acts-ensure-thyroid-drugs-dont-lose-potency-expiration-date
- Statista. Statista. 2023 [cited 2023 Jun 4]. Levothyroxine prescriptions number U.S. 2004-2020. Available from: https://www.statista.com/statistics/780284/levothyroxine-prescriptions-number-in-the-us/
- Gottwald-Hostalek U, Tayrouz Y. Real world clinical experience with a new formulation of levothyroxine engineered to meet new and stricter regulatory requirements. Current Medical Research and Opinion. 2021 Dec 2;37(12):2093–8.
- Melmed S, Koenig R, Rosen C, Auchus R, Goldfine A. Williams Textbook of Endocrinology - 14th Edition [Internet]. 14th ed. Elsevier; 2019 [cited 2020 May 30]. 1792 p. Available from: https://www.elsevier.com/books/williams-textbook-of-endocrinology/melmed/978-0-323-55596-8
- Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Boelaert K, Šumilo D, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ. 2019 Sep 3;366:l4892.
- Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010 Jan;95(1):186–93.
- Lipp HP, Hostalek U. A new formulation of levothyroxine engineered to meet new specification standards. Current Medical Research and Opinion. 2019 Jan 2;35(1):147–50.
- Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials. Current Medical Research and Opinion. 2017 Feb 1;33(2):169–74.
- EMA-CHMP. Levothyroxine tablets 12.5 mcg, 25 mcg, 50 mcg,75 mcg, 100 mcg and 200 mcg (and additional strengths within the range) product-specific bioequivalence guidance [Internet]. European Medicines Agency; 2020 [cited 2023 Apr 4]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/levothyroxine-tablets-125-mcg-25-mcg-50-mcg-75-mcg-100-mcg-200-mcg-additional-strengths-within-range_en.pdf
- Lehnert H, Castello-Bridoux C, Channaiah B, Martiniere K, Hildemann S, Wémeau JL. Comparison of Safety Profiles of the New and Old Formulations of Levothyroxine in a First Global Introduction in France. Exp Clin Endocrinol Diabetes. 2021 Dec;129(12):908–17.
- Razvi S, Hostalek U. Therapeutic challenges in the application of serum thyroid stimulating hormone testing in the management of patients with hypothyroidism on replacement thyroid hormone therapy: a review. Curr Med Res Opin. 2019 Jul;35(7):1215–20.
- Food and Drug Administration. Guidance for Industry: Levothyroxine Sodium Tablets — In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing [Internet]. Food and Drug Administration; 2001 [cited 2023 Apr 4]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/levothyroxine-sodium-tablets-in-vivo-pharmacokinetic-and-bioavailability-studies-and-in-vitro-dissolution
- Duntas LH, Jonklaas J. Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient’s Lifetime. Adv Ther. 2019;36(Suppl 2):30–46.
- Krendyukov A, Nasy D. Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives. Pharm Med. 2020 Aug 1;34(4):247–56.
- Brown P, Bahri P. ‘Engagement’ of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework. Eur J Clin Pharmacol. 2019 Sep 1;75(9):1181–92.
- Colucci P et al. A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism. European Endocrinology 2013;9(1):40–7.
- MRHA. Levothyroxine Tablet Products: A Review of Clinical & Quality Considerations. 2013. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420997/CHM_Review_for_MHRA_website_Levothyroxine_sodium_FINAL_04_Jan_2013.pdf. Accessed December 2023